These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 14571412)

  • 21. The application of prostate specific membrane antigen in CART‑cell therapy for treatment of prostate carcinoma (Review).
    Ullah K; Addai Peprah F; Yu F; Shi H
    Oncol Rep; 2018 Dec; 40(6):3136-3143. PubMed ID: 30542701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
    Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
    Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy for prostate cancer: walk, don't run.
    Drake CG
    J Clin Oncol; 2009 Sep; 27(25):4035-7. PubMed ID: 19635998
    [No Abstract]   [Full Text] [Related]  

  • 24. Targeted therapies for prostate cancer against the prostate specific membrane antigen.
    Elsässer-Beile U; Bühler P; Wolf P
    Curr Drug Targets; 2009 Feb; 10(2):118-25. PubMed ID: 19199907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA vaccines: an active immunization strategy for prostate cancer.
    Wolchok JD; Gregor PD; Nordquist LT; Slovin SF; Scher HI
    Semin Oncol; 2003 Oct; 30(5):659-66. PubMed ID: 14571413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
    Gade TP; Hassen W; Santos E; Gunset G; Saudemont A; Gong MC; Brentjens R; Zhong XS; Stephan M; Stefanski J; Lyddane C; Osborne JR; Buchanan IM; Hall SJ; Heston WD; Rivière I; Larson SM; Koutcher JA; Sadelain M
    Cancer Res; 2005 Oct; 65(19):9080-8. PubMed ID: 16204083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
    Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ
    Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer.
    Schellhammer PF; Hershberg RM
    World J Urol; 2005 Feb; 23(1):47-9. PubMed ID: 15647927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer vaccines: current status and future potential.
    Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
    BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
    Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
    Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the prostate-specific membrane antigen for prostate cancer therapy.
    Bühler P; Wolf P; Elsässer-Beile U
    Immunotherapy; 2009 May; 1(3):471-81. PubMed ID: 20635963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor vaccines for the management of prostate cancer.
    McNeel DG; Disis ML
    Arch Immunol Ther Exp (Warsz); 2000; 48(2):85-93. PubMed ID: 10807048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Active immunotherapy of prostate cancer with a focus on dendritic cells].
    Thomas-Kaskel AK; Veelken H
    Actas Urol Esp; 2007 Jun; 31(6):668-79. PubMed ID: 17896564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
    Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
    Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted treatment of prostate cancer.
    Wang X; Yin L; Rao P; Stein R; Harsch KM; Lee Z; Heston WD
    J Cell Biochem; 2007 Oct; 102(3):571-9. PubMed ID: 17685433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.